FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 146 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR 31-Year Breast Cancer Survivor Celebrates 100th Birthday with Drive-By Mardi Gras... December 29, 2020 Risk Tool Predicts Severe Chemotherapy Toxicity in Elderly Patients with Early... January 21, 2021 ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers... August 24, 2020 A New FDA Approval Furthers the Role of Genomics in Cancer... July 8, 2020 Load more HOT NEWS Living With Stage 4 Lung Cancer: How Genomic Testing Is Helping... COVID-19 Vaccines Are Safe for People Receiving Cancer Immunotherapy, Study Confirms Bride Diagnosed with Stage IV Triple-Negative Breast Cancer 6 Months Before... ΟΡΘΟΚΟΛΙΚΟΣ ΚΑΡΚΙΝΟΣ
